Laboratory of neuroregeneration, Federal State Budgetary Institution “Federal center of brain research and neurotechnologies” of the Federal Medical Biological Agency of Russia, Moscow, Moskva, Russia
Mr. Vladimir Kovalev
Laboratory of neuroregeneration, Federal State Budgetary Institution “Federal center of brain research and neurotechnologies” of the Federal Medical Biological Agency of Russia, Moscow, Moskva, Russia
Passage of light through a suspension is accompanied by a competition of processes of absorption and scattering for each individual particle. As a result, a hypochromism phenomenon (a decrease in the extinction coefficient) takes place. The hypochromism value increases with the growth of a particle sizes or its refractive index. Since Tyndall’s light scattering in a suspension where the size of every particle is considerably larger than the wavelength weakly depends on the wavelength, the absorption (or excitation) spectrum is almost uniformly attenuated. A simple method for determination of the true extinction coefficients of the absorption and excitation spectra of diluted suspensions which have no multiple light scattering is proposed. Experimental data on the spectra of hemoglobin in erythrocytes, actinomycin in DNA, and flavines in mitochondria are discussed.
Alzheimer’s disease (AD) is a severe neurodegenerative condition affecting millions worldwide. Prevalence of AD correlates with increased life expectancy and aging population in the developed countries. Considering that AD is a multifactorial disease involving various pathological processes such as synaptic dysfunction, neuroinflammation, oxidative stress, and improper protein folding, a comprehensive approach targeting multiple pathways may prove effective in slowing the disease progression. Cellular therapy and its further development in the form of cell vesicle and particularly mitochondrial transplantation represent promising approaches for treating neurodegeneration. The use of synaptosomes, due to uniqueness of their contents, could mark a new stage in the development of comprehensive therapies for neurodegenerative diseases, particularly AD. Synaptosomes contain unique memory mitochondria, which differ not only in size but also in functionality compared to the mitochondria in the neuronal soma. These synaptosomal mitochondria actively participate in cellular communication and signal transmission within synapses. Synaptosomes also contain other elements such as their own protein synthesis machinery, synaptic vesicles with neurotransmitters, synaptic adhesion molecules, and microRNAs – all crucial for synaptic transmission and, consequently, cognitive processes. Complex molecular ensemble ensures maintenance of the synaptic autonomy of mitochondria. Additionally, synaptosomes, with their affinity for neurons, can serve as an optimal platform for targeted drug delivery to nerve cells. This review discusses unique composition of synaptosomes, their capabilities and advantages, as well as limitations of their suggested use as therapeutic agents for treating neurodegenerative pathologies, particularly AD.
Spinal cord injury (SCI) is a neurological condition often resulting in permanent motor and sensory deficits, for which effective treatments remain limited. RNA interference (RNAi) is a post-transcriptional mechanism of the downregulation of gene expression mediated by small interfering RNAs. RNAi has demonstrated therapeutic efficacy in various neurological disorders, positioning it as a promising yet underexplored therapeutic strategy for SCI. Here, we provide a focused overview of the key pathological processes in SCI, including primary mechanical injury and secondary cascades such as inflammation, mitochondrial dysfunction, excitotoxicity, oxidative stress, multiple forms of cell death, and others. The potential of RNAi to selectively silence genes implicated in these pathological processes, thereby enhancing neuroprotection and functional recovery, is highlighted. We point out that not only protein-coding genes, but non-coding RNAs (ncRNAs) are suitable targets for RNAi. Novel RNAi tools such as CRISPR-Cas13 might revolutionize the field and offer new opportunities for SCI therapy. However, despite all these promising findings, relevant translational studies of RNAi remain scarce. Challenges related to delivery methods, long-term efficacy, and cell-specific targeting must be addressed. Importantly, combining RNAi with other strategies such as cell- or biomaterial-based therapies may enhance therapeutic outcomes. Future investigations should prioritize systematic comparisons of RNAi targets and delivery systems, ideally at single-cell resolution and in different SCI models, to identify the most relevant molecular pathways for clinical translation. Overall, RNAi represents a compelling but still underdeveloped approach for SCI therapy, requiring continued refinement to reach clinical application.
1 December 2019 in Biochemistry and Biophysics Reports
A number of properties of the smallest (less than 0.2 μm) germinal proto-mitochondria (PRMC) from rat liver have been studied. These PRMC were obtained by filtering the light fraction of hepatic mitochondria (MC) through calibrated millipore membranes. Germinal PRMC contain in general the same proteins as MC. However, they have the reduced content of flavoproteins and zero cytochrome oxidase. Germinal PRMC, in contrast to MC, almost does not contain the "aging pigment" - lipofuscin. They have DNA; the DNA/protein ratio in them is much higher than in MC, i.e. they are poor in protein. The obtained results support the earlier assumption that MC in specialized animal cells can arise from germinal PRMC - particles smaller than 0.2 μm containing DNA. It is assumed that the DNA molecules enter to cytoplasm during degradation of old MC serves as a seed for the formation of PRMC (with the connection of nuclear DNA).
Alzheimer’s disease (AD) is a severe neurodegenerative disease that affects millions of people around the world. The increasing prevalence of AD correlates with increasing life expectancy and aging populations in developed countries. Since AD is a multifactorial disease and includes various pathological processes, such as: synaptic dysfunction, neuroinflammation, oxidative stress, protein misfolding, etc., an integrated approach aimed simultaneously at several targets may be effective and slow down the progression of the disease. Cell therapy and its further development in the form of transplantation of cellular vesicles and especially mitochondria are a very promising approach for the treatment of neurodegeneration. The use of synaptosomes, due to the uniqueness of their content, may become a new stage in the development of complex therapy for neurodegenerative diseases and AD in particular. This review discusses the preparation and composition of synaptosomes, as well as the possibilities and advantages of their use as transporters for the delivery of synaptic mitochondria and other biologically active substances to the brain.